

# International Nonproprietary Names for Pharmaceutical Substances (INN)

---

Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996*. The statements indicating action and use are based largely on information supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will neither be revised nor included in the Cumulative Lists of INNs.

## Dénominations communes internationales des Substances pharmaceutiques (DCI)

Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996*. Les mentions indiquant les propriétés et les indications des substances sont fondées sur les renseignements communiqués par le fabricant. Elles ne visent qu'à donner une idée de l'utilisation potentielle des nouvelles substances au moment où elles sont l'objet de propositions de DCI. L'OMS n'est pas en mesure de confirmer ces déclarations ni de faire de commentaires sur l'efficacité du mode d'action ainsi décrit. En raison de leur caractère provisoire, ces informations ne figureront pas dans les listes récapitulatives de DCI.

## Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

De conformidad con lo que dispone el párrafo 3 del "Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas", se comunica por el presente anuncio que las denominaciones detalladas en las páginas siguientes están sometidas a estudio por la Organización Mundial de La Salud como Denominaciones Comunes Internacionales Propuestas. La inclusión de una denominación en las listas de las DCI Propuestas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996*. Las indicaciones sobre acción y uso que aparecen se basan principalmente en la información facilitada por los fabricantes. Esta información tiene por objeto dar una idea únicamente de las posibilidades de aplicación de las nuevas sustancias a las que se asigna una DCI Propuesta. La OMS no está facultada para respaldar esas indicaciones ni para formular comentarios sobre la eficacia de la acción que se atribuye al producto. Debido a su carácter provisional, esos datos descriptivos no deben incluirse en las listas recapitulativas de DCI.

## Proposed International Nonproprietary Names: List 78

Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, i.e., for **List 78 Proposed INN not later than 15 May 1998**.

## Dénominations communes internationales proposées: Liste 78

Des observations ou des objections formelles à l'égard des dénominations proposées peuvent être adressées par toute personne au Programme des Dénominations communes internationales de l'Organisation mondiale de la Santé dans un délai de quatre mois à compter de la date de leur publication dans *WHO Drug Information*, c'est-à-dire pour la **Liste 78 de DCI Proposées le 15 mai 1998 au plus tard**.

## Denominaciones Comunes Internacionales Propuestas: Lista 78

Cualquier persona puede dirigir observaciones u objeciones respecto de las denominaciones propuestas, al Programa de Denominaciones Comunes Internacionales de la Organización Mundial de la Salud, en un plazo de cuatro meses, contados desde la fecha de su publicación en *WHO Drug Information*, es decir, para la **Lista 78 de DCI Propuestas el 15 de mayo de 1998 a más tardar**.

<i>Proposed INN</i> (Latin, English, French, Spanish)	<i>Chemical name or description: Action and use: Molecular formula</i> <i>Chemical Abstracts Service (CAS) registry number: Graphic formula</i>
<i>DCI Proposée</i>	<i>Nom chimique ou description: Propriétés et indications: Formule brute</i> <i>Numéro dans le registre du CAS: Formule développée</i>
<i>DCI Propuesta</i>	<i>Nombre químico o descripción: Acción y uso: Fórmula empírica</i> <i>Número de registro del CAS: Fórmula desarrollada</i>

### abarelixum

abarelix

*N*-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-*N*-methyl-L-tyrosyl-D-asparaginyll-leucyl-*N*<sup>6</sup>-isopropyl-L-lysyl-L-prolyl-D-alaninamide

*luteinizing-hormone-releasing-hormone inhibitor*

abarélix

[*N*-acétyl-3-(naphthalén-2-yl)-D-alanyl]-(4-chloro-D-phénylalanyl)-[3-(pyridin-3-yl)-D-alanyl]-L-séryl-(*N*-méthyl-L-tyrosyl)-D-asparaginyll-leucyl-[*N*<sup>6</sup>-(1-méthyléthyl)-L-lysyl]-L-prolyl-D-alaninamide


*inhibiteur de l'hormone de libération de la lutéostimuline*

abarelix

*N*-acetil-3-(2-naftil)-D-alanil-4-cloro-D-fenilalanil-3-(3-piridil)-D-alanil-L-seril-*N*-metil-L-tirosil-D-asparaginil-L-leucil-*N*<sup>6</sup>-isopropil-L-lisil-L-prolil-D-alaninamida

*inhibidor de la hormona de liberación de hormona luteinizante*

C<sub>72</sub>H<sub>95</sub>ClN<sub>14</sub>O<sub>14</sub>      183552-38-7



**acidum minodronicum**

minodronic acid

(1-hydroxy-2-imidazo[1,2-a]pyridin-3-ylethylidene)diphosphonic acid  
*calcium regulator*


acide minodronique

acide [1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)éthylidène]diphosphonique  
*régulateur du calcium*

ácido minodrónico

ácido 1-hidroxi-2-imidazo[1,2-a]piridin-3-iletilideno)difosfónico  
*regulador del calcio*C<sub>9</sub>H<sub>12</sub>N<sub>2</sub>O<sub>7</sub>P<sub>2</sub>

127657-42-5

**atreleutonum**

atreleuton

1-[(*R*)-3-[5-(*p*-fluorobenzyl)-2-thienyl]-1-methyl-2-propynyl]-1-hydroxyurea  
*antiasthmatic*


atréleuton

1-[(1*R*)-3-[5-(4-fluorobenzyl)thiophén-2-yl]-1-méthylprop-2-ynyl]-1-hydroxyurée  
*antiasthmatique*

atreleutón

1-[(*R*)-3-[5-(*p*-fluorobencil)-2-tienil]-1-metil-2-propinil]-1-hidroxiurea  
*antiasmático*C<sub>16</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>2</sub>S

154355-76-7

**aviptadilium**

aviptadil

L-histidyl-L-seryl-L-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutaminyll-L-methionyl-L-alanyl-L-valyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-asparaginyll-L-seryl-L-isoleucyl-L-leucyl-L-asparagine  
*vasodilatator*


aviptadil

L-histidyl-L-séryl-L-aspartyl-L-alanyl-L-valyl-L-phénylalanyl-L-thréonyl-L-aspartyl-L-asparaginyll-L-tyrosyl-L-thréonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutaminyll-L-méthionyl-L-alanyl-L-valyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-asparaginyll-L-séryl-L-isoleucyl-L-leucyl-L-asparagine  
*vasodilatateur*


**aviptadil**  
 L-histidil-L-seril-L-aspartil-L-alanil-L-valil-L-fenilalanil-L-treonil-L-aspartil-L-asparaginil-L-tirosil-L-treonil-L-arginil-L-leucil-L-arginil-L-lisil-L-glutaminil-L-metionil-L-alanil-L-valil-L-lisil-L-lisil-L-tirosil-L-leucil-L-asparaginil-L-seril-L-isoleucil-L-leucil-L-asparagina  
*vasodilatador*  
 C<sub>147</sub>H<sub>238</sub>N<sub>44</sub>O<sub>42</sub>S      40077-57-4  
 His–Ser–Asp–Ala–Val–Phe–Thr–Asp–Asn–Tyr–Thr–Arg–Leu–Arg–  
 Lys–Gln–Met–Ala–Val–Lys–Lys–Tyr–Leu–Asn–Ser–Ile–Leu–Asn

**bepotastinum**

bepotastine  
 (+)-4-[[*(S)*-*p*-chloro-2-pyridylbenzyl]oxy]-1-piperidinebutyric acid  
*antialérgico*  
 bépotastine  
 acide (+)-4-[4-[[*(S)*-(4-chlorophényl)(pyridin-2-yl)méthoxy]pipéridin-1-yl]butanoïque  
*antialérgique*  
 bepotastina  
 ácido (+)-4-[[*(S)*-*p*-cloro-2-piridilbencil]oxi]-1-piperidinabutírico  
*antialérgico*  
 C<sub>21</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>3</sub>      125602-71-3

**bibapcitidum**

bibapcitide  
 13,13'-[oxybis[methylene(2,5-dioxo-1,3-pyrrolidinediyl)]]bis[*N*-(mercaptoacetyl)-*D*-tyrosyl-*S*-(3-aminopropyl)-L-cysteinylglycyl-L- $\alpha$ -aspartyl-L-cysteinylglycylglycyl-*S*-(acetamidomethyl)-L-cysteinylglycyl-*S*-(acetamidomethyl)-L-cysteinylglycylglycyl-L-cysteinamide cyclic (1-5),(1'-5')-bis(sulfide)  
*diagnostic agent*  
 bibapcitide  
 (1-5),(1'-5')-bis(sulfure cyclique) du 13,13'-[oxybis[méthylène(2,5-dioxopyrrolidine-1,3-diyl)]]bis[[*N*-(sulfanylacétyl)-*D*-tyrosyl]-*S*-(3-aminopropyl)-L-cystéinyl]-glycyl-L-aspartyl-L-cystéinyl-glycyl-glycyl-*S*-[(acétylamino)méthyl]-L-cystéinyl]-glycyl-*S*-[(acétylamino)méthyl]-L-cystéinyl]-glycyl-glycyl-L-cystéinamide]  
*produit à usage diagnostique*  
 bibapcitida  
 (1-5),(1'-5')-bis(sulfuro cíclico) de 13,13'-[oxibis[metileno(2,5-dioxo-1,3-pirrolidinadiil)]]bis[*N*-(mercaptoacetil)-*D*-tiroxil-*S*-(3-aminopropil)-L-cisteinilglicil-L- $\alpha$ -aspartil-L-cisteinilglicilglicil-*S*-(acetamidometil)-L-cisteinilglicil-*S*-(acetamidometil)-L-cisteinilglicilglicil-L-cisteinamida cíclica  
*agente de diagnóstico*

C<sub>112</sub>H<sub>162</sub>N<sub>36</sub>O<sub>43</sub>S<sub>10</sub> 153507-46-1**biricodarum**

biricodar

4-(3-pyridyl)-1-[3-(3-pyridyl)propyl]butyl (S)-1-[(3,4,5-trimethoxyphenyl)glyoxyloyl]piperolate  
*multidrug resistant inhibitor, antineoplastic*

biricodar


(2S)-1-[2-oxo-2-(3,4,5-triméthoxyphényl)acétyl]pipéridine-2-carboxylate de 4-(pyridin-3-yl)-1-[3-(pyridin-3-yl)propyl]butyle  
*inhibiteur de la multirésistance aux médicaments antinéoplastiques*

biricodar

(S)-1-[(3,4,5-triméthoxyfenil)glioxiloil]piperolato de 4-(3-piridil)-1-[3-(piridil)propil]butilo  
*inhibidor de la resistencia a multiples fármacos antineoplástico*

C<sub>34</sub>H<sub>41</sub>N<sub>3</sub>O<sub>7</sub>

174254-13-8

**carafibanum**

carafiban

ethyl (S)-β-[2-[(S)-4-(p-aminophenyl)-4-methyl-2,5-dioxo-1-imidazolidinyl]acetamido]hydrocinnamate  
*fibrinogen receptor antagonist*

carafiban


(3S)-3-[[2-[(4S)-4-(4-carbamimidoylphényl)-4-méthyl-2,5-dioxoimidazolidin-1-yl]acétyl]amino]-3-phénylpropanoate d'éthyle  
*antagoniste du récepteur du fibrinogène*

carafibán

(S)-β-[2-[(S)-4-(p-amidinofenil)-4-metil-2,5-dioxo-1-imidazolidinil]acetamido]hidrocinnamato de etilo  
*antagonista del receptor del fibrinógeno*

C<sub>24</sub>H<sub>27</sub>N<sub>5</sub>O<sub>5</sub>

177563-40-5

**clevudinum**

clevudine

1-(2-deoxy-2-fluoro-β-L-arabinofuranosyl)thymine  
*antiviral*


clévudine

1-(2-fluoro-2-désoxy-β-L-arabinofuranosyl)-5-méthylpyrimidine-2,4(1*H*,3*H*)-  
dione  
*antiviral*

clevudina

1-(2-desoxi-2-fluoro-β-L-arabinofuranosil)timina  
*antiviral*C<sub>10</sub>H<sub>13</sub>FN<sub>2</sub>O<sub>5</sub>

163252-36-6

**declopramidum**

declopramide

4-amino-3-chloro-*N*-[2-(diethylamino)ethyl]benzamide  
*radiosensitizing agent*


déclopramide

4-amino-3-chloro-*N*-[2-(diéthylamino)éthyl]benzamide  
*radiosensibilisant*

declopramida

4-amino-3-cloro-*N*-[2-(dielamino)etil]benzamida  
*agente sensibilizante para radioterapia*C<sub>13</sub>H<sub>20</sub>ClN<sub>3</sub>O

891-60-1



**denileukinum diftitoxum**

denileukin diftitox

*N*-L-methionyl-387-L-histidine-388-L-alanine-1-388-toxin (*Corynebacterium diphtheriae* strain C7) (388-2')-protein with 2-133-interleukin 2 (human clone pTIL2-21a)  
*immunomodulator*

dénileukine diftitox

*N*-L-méthionyl[387-L-histidine-388-L-alanine]-(1-388)-toxine (souche C7 de *Corynebacterium diphtheriae*)-(388-2')-(2-133)-interleukine 2 (clone pTIL2-21a humain)  
*immunomodulateur*

denileukina diftitox

*N*-L-metionil-387-L-histidina-388-L-alanina-1-388-toxina (cepa C7 de *Corynebacterium diphtheriae*) (388-2')-(2-133)-interleukin 2 (clon humano pTIL2-21a)  
*inmunomodulador*

C<sub>2560</sub>H<sub>4036</sub>N<sub>678</sub>O<sub>799</sub>S<sub>17</sub> 173146-27-5

```

MGADDVVDSS  KSFVMENFSS  YHGTPGYVD  SIQKGIQKPK
SGTQGNYYYY  WKGFYSTDNK  YDAAGYSVDN  ENPLSGKAGG
VVKVTYPGLT  KVLALKVDNA  ETIKKELGLS  LTEPLMEQVG
TEEFIKRFGD  GASRVVLSLP  FAEGSSSVEY  INNWEQAKAL
SVELEINFET  RGKRGQDAMY  EYMAQACAGN  RVRRSVGSLL
SCINLDWDVI  RDKTGTKIES  LKEHGPIKNK  MSES PNKTVS
EEKAKQYLEE  FHQTALEHPE  LSELKTVTGT  NPVFAGANYA
AWAVNVAQVI  DSETADNLEK  TTAALSILPG  IGSVMGIADG
AVHHNTEEIV  AQSIALSSLM  VAQAIPLVGE  LVDIGFAAYN
FVESIINLFQ  VVHNSYNRPA  YSPGHKTHAP  TSSSTKKTQL
QLEHLLLDLQ  MILNGINNYK  NPKLTRMLTF  KFYMPKKATE
LKHLQCLEEE  LKPLEEVLNL  AQSKNFHLRP  RDLISNINVI
VLELKGSETT  FMCEYADETA  TIVEFLNRWI  TFCQSIISTL
T

```

**dutasteridum**

dutasteride

$\alpha,\alpha,\alpha,\alpha',\alpha'$ -hexafluoro-3-oxo-4-aza-5 $\alpha$ -androst-1-ene-17 $\beta$ -carboxy-2',5'-xylidide  
*testosterone reductase inhibitor*

dutastéride


*N*-[2,5-bis(trifluorométhyl)phényl]-3-oxo-4-aza-5 $\alpha$ -androst-1-ène-17 $\beta$ -carboxamide  
*inhibiteur de la réductase de la testostérone*

dutasterida

$\alpha,\alpha,\alpha,\alpha',\alpha'$ -hexafluoro-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxi-2',5'-xilidida  
*inhibidor de la reductase de la testosterona*

C<sub>27</sub>H<sub>30</sub>F<sub>6</sub>N<sub>2</sub>O<sub>2</sub>

164656-23-9

**ecefloxacinum**

ecefloxacin

(+)-7-[(1*R*,5*S*,6*S*)-6-amino-1-methyl-3-azabicyclo[3.2.0]hept-3-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid  
*antibacterial*

écéfloxacine


acide (+)-7-[(1*R*,5*S*,6*S*)-6-amino-1-méthyl-3-azabicyclo[3.2.0]hept-3-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylique  
*antibactérien*

ecenofloxacin

ácido (+)-7-[(1*R*,5*S*,6*S*)-6-amino-1-metil-3-azabicyclo[3.2.0]hept-3-il]-1-ciclopropil-6-fluoro-1,4-dihidro-4-oxo-1,8-naftiridina-3-carboxílico  
*antibacteriano*

C<sub>19</sub>H<sub>21</sub>FN<sub>4</sub>O<sub>3</sub>

162301-05-5

**efavirenzum**

efavirenz

(*S*)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2*H*-3,1-benzoxazin-2-one  
*antiviral*

éfavirenz


(4*S*)-6-chloro-4-(cyclopropyléthynyl)-4-(trifluorométhyl)-1,4-dihydro-2*H*-3,1-benzoxazin-2-one  
*antiviral*

efavirenzo

(*S*)-6-cloro-4-(ciclopropiletinil)-1,4-dihidro-4-(trifluorometil)-2*H*-3,1-benzoxazin-2-ona  
*antiviral*

C<sub>14</sub>H<sub>9</sub>ClF<sub>3</sub>NO<sub>2</sub>

154598-52-4

**embusartanum**

embusartan

methyl 6-butyl-1-[2-fluoro-4-(*o*-1*H*-tetrazol-5-yl)phenyl]benzyl]-1,2-dihydro-2-oxoisonicotinate  
*angiotensin II receptor antagonist*

embusartan


6-butyl-1-[[[3-fluoro-2'-(1*H*-tétrazole-5-yl)biphényl-4-yl]méthyl]-2-oxo-1,2-dihydropyridine-4-carboxylate de méthyle  
*antagoniste du récepteur de l'angiotensine II*

embusartán

6-butil-1-[2-fluoro-4-(*o*-1*H*-tetrazol-5-ilfenil)benzil]-1,2-dihidro-2-oxoisonicotinato de metilo  
*antagonista del receptor de angiotensina II*

C<sub>25</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>3</sub>

156001-18-2

**eptifibatidum**

eptifibatide

*N*<sup>6</sup>-amidino-*N*<sup>2</sup>-(3-mercaptopropionyl)-L-lysylglycyl-L- $\alpha$ -aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1-6)-disulfide  
*platelet aggregation inhibitor; fibrinogen receptor antagonist*

eptifibatide


(1-6)-disulfure cyclique de [*N*<sup>6</sup>-carbamimidoyl-*N*<sup>2</sup>-(3-sulfanylpropanoyl)-L-lysyl]-glycyl-L-aspartyl-L-tryptophyl-L-prolyl-L-cystéinamide  
*antiagrégant plaquettaire; antagoniste du récepteur du fibrinogène*

eptifibatida

(1-6)-disulfuro cíclico de *N*<sup>6</sup>-amidino-*N*<sup>2</sup>-(3-mercaptopropionil)-L-lisilglicil-L- $\alpha$ -aspartil-L-triptofil-L-prolil-L-cisteinamida  
*inhibidor de la agregación plaquetaria; antagonista del receptor del fibrinógeno*

C<sub>35</sub>H<sub>49</sub>N<sub>11</sub>O<sub>9</sub>S<sub>2</sub>

148031-34-9



**fandofloxacinum**

fandofloxacin

6-fluoro-1-(5-fluoro-2-pyridyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid  
*antibacterial*


fandofloxacine

acide 6-fluoro-1-(5-fluoropyridin-2-yl)-7-(4-méthylpipérazin-1-yl)-4-oxo-1,4-dihydroquinoléine-3-carboxylique  
*antibactérien*

fandofloxacino

ácido 6-fluoro-1-(5-fluoro-2-piridil)-1,4-dihidro-7-(4-metil-1-piperazinil)-4-oxo-3-quinolinacarboxílico  
*antibacteriano*C<sub>20</sub>H<sub>18</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub>

164150-85-0

**fasoracetamum**


fasoracetam

(+) -1-[[*(R)*-5-oxo-2-pyrrolidinyl]carbonyl]piperidine  
*nootropic agent*

fasoracétam

(+) -1-[[*(2R)*-5-oxopyrrolidin-2-yl]carbonyl]pipéridine  
*nootrope*

fasoracetam

(+) -1-[[*(R)*-5-oxo-2-pirrolidinil]carbonil]piperidina  
*nootropo***fidarestatum**

fidarestat

(+) -*(2S,4S)*-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide  
*aldose reductase inhibitor*

fidarestat


(+) -*(2S,4S)*-6-fluoro-2',5'-dioxo-2,3-dihydrospiro[4*H*-chromène-4,4'-imidazolidine]-2-carboxamide  
*inhibiteur de l'aldose réductase*

fidarestat

(+) -*(2S,4S)*-6-fluoro-2',5'-dioxoespiro[4*H*-croman-4,4'-imidazolidina]-2-carboxamida  
*inhibidor de la reductasa de aldosas*

C<sub>12</sub>H<sub>10</sub>FN<sub>3</sub>O<sub>4</sub>

136087-85-9

**frovatriptanum**

frovatriptan

(*R*)-5,6,7,8-tetrahydro-6-(methylamino)carbazole-3-carboxamide  
*serotonin receptor agonist*

frovatriptan


(6*R*)-6-(méthylamino)-6,7,8,9-tétrahydro-5*H*-carbazole-3-carboxamide  
*agoniste des récepteurs de la sérotonine*

frovatriptán

(*R*)-5,6,7,8-tetrahydro-6-(metilamino)carbazol-3-carboxamide  
*agonista de los receptores de la serotonina*

C<sub>14</sub>H<sub>17</sub>N<sub>3</sub>O

158747-02-5

**fulvestrantum**

fulvestrant


7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17 $\beta$ -diol  
*antiestrogen*

fulvestrant

7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triène-3,17 $\beta$ -diol  
*antiestrogène*

fulvestrant

7 $\alpha$ -[9-[(4,4,5,5,5-pentafluoropentil)sulfinil]nonil]estra-1,3,5(10)-trieno-3,17 $\beta$ -diol  
*antiestrógeno*

C<sub>32</sub>H<sub>47</sub>F<sub>5</sub>O<sub>3</sub>S

**ibutamorenium**

ibutamoren

2-amino-*N*-[(*R*)-2-(benzyloxy)-1-[[1-(methylsulfonyl)spiro[indoline-3,4'-piperidin]-1'-yl]carbonyl]ethyl]-2-methylpropanamide  
*growth hormone release stimulating peptide*

ibutamoren


2-amino-*N*-[(1*R*)-1-(benzyloxy)méthyl]-2-[1-(méthylsulfonyl)-1,2-dihydrospiro[indole-3,4'-pipéridin]-1'-yl]-2-oxoéthyl]-2-méthylpropanamide  
*peptide stimulant la libération de l'hormone de croissance*

ibutamoreno

2-amino-*N*-[(*R*)-2-(benciloxi)-1-[[1-(metilsulfonil)espiro[indolina-3,4'-piperidin]-1'-il]carbonil]etil]-2-metilpropionamida  
*peptido estimulante de la liberación de la hormona del crecimiento*

C<sub>27</sub>H<sub>36</sub>N<sub>4</sub>O<sub>5</sub>S

159634-47-6

**ipamorelinum**

ipamorelin

2-methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysineamide  
*growth factor*

ipamoréline


(2-méthyl-L-alanyl)-L-histidyl-[3-(naphthalén-2-yl)-D-alanyl]-D-phénylalanyl-L-lysineamide  
*facteur de croissance*

ipamorelina

2-metilalanil-L-histidil-3-(2-naftil)-D-alanil-D-fenilalanil-L-lisinaamida  
*factor de crecimiento*

C<sub>38</sub>H<sub>49</sub>N<sub>9</sub>O<sub>5</sub>

170851-70-4

**levocetirizinum**

levocetirizine

[2-[4-[(*R*)-*p*-chloro- $\alpha$ -phenylbenzyl]-1-piperazinyl]ethoxy]acetic acid  
*histamine H<sub>1</sub>-receptor antagonist*

lévocétirizine


acide 2-[2-[4-[(*R*)-(4-chlorophényl)phénylméthyl]pipérazin-1-yl]éthoxy]acétique  
*antagoniste des récepteurs H<sub>1</sub> de l'histamine*

levocetirizina

ácido [2-[4-[(*R*)-*p*-cloro- $\alpha$ -fenilbencil]-1-piperazinil]etoxi]acético  
*antagonista de los receptores H<sub>1</sub> de la histamina*

C<sub>21</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>3</sub>

130018-77-8

**levosalbutamolum**

levosalbutamol

*(R)*-α<sup>1</sup>-[(*tert*-butylamino)methyl]-4-hydroxy-*m*-xylene-α,α<sup>1</sup>-diol  
*antiasthmatic*


lévosalbutamol

*(1R)*-2-[(1,1-diméthyléthyl)amino]-1-[4-hydroxy-3-(hydroxyméthyl)phényl]éthanol  
*antiasthmaticque*

levosalbutamol

*(R)*-α<sup>1</sup>-[(*terc*-butilamino)metil]-4-hidroxi-*m*-xileno-α,α<sup>1</sup>-diol  
*antiasmático*C<sub>13</sub>H<sub>21</sub>NO<sub>3</sub>

34391-04-3

**lodenosinum**

lodenosine

9-(2,3-dideoxy-2-fluoro-β-D-*threo*-pentofuranosyl)adenine  
*antiviral*


lodénosine

9-(2-fluoro-2,3-didésoxy-β-D-*thréo*-pentofuranosyl)-9*H*-purine-6-amine  
*antiviral*

lodenosina

9-(2,3-didesoxi-2-fluoro-β-D-*treo*-pentofuranosil)adenina  
*antiviral*C<sub>10</sub>H<sub>12</sub>FN<sub>5</sub>O<sub>2</sub>

110143-10-7



**lotrafibanum**

lotrafiban

(*S*)-2,3,4,5-tetrahydro-4-methyl-3-oxo-7-[[4-(4-piperidyl)piperidino]carbonyl]-1*H*-1,4-benzodiazepine-2-acetic acid  
*fibrinogen receptor antagonist*

lotrafiban


acide 2-[(2*S*)-7-[(4,4'-bipiperidinyl-1-yl)carbonyl]-4-méthyl-3-oxo-2,3,4,5-tétrahydro-1*H*-1,4-benzodiazépin-2-yl]acétique  
*antagoniste du récepteur du fibrinogène*

lotrafibán

ácido (*S*)-2,3,4,5-tetrahydro-4-metil-3-oxo-7-[[4-(4-piperidil)piperidino]carbonil]-1*H*-1,4-benzodiazepina-2-acético  
*antagonista del receptor del fibrinógeno*

C<sub>22</sub>H<sub>32</sub>N<sub>4</sub>O<sub>4</sub>

171049-14-2

**meluadrinum**

meluadrine

(-)-(*R*)-α-[(*tert*-butylamino)methyl]-2-chloro-4-hydroxybenzyl alcohol  
*β-adrenoceptor agonist*

méluadrine


(-)-(1*R*)-1-(2-chloro-4-hydroxyphényl)-2-[(1,1-diméthyléthyl)amino]éthanol  
*agoniste β-adrénergique*

meluadrina

alcohol (-)-(*R*)-α-[(*tert*-butilamino)metil]-2-cloro-4-hidroxibencílico  
*agonista de los receptores β-adrenérgicos*

C<sub>12</sub>H<sub>18</sub>ClNO<sub>2</sub>

134865-33-1

**mespiperonum (<sup>11</sup>C)**mespiperone (<sup>11</sup>C)


8-[3-(*p*-fluorobenzoyl)propyl]-3-[<sup>11</sup>C]methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one  
*radiodiagnostic agent*

mespiperone (<sup>11</sup>C)

8-[4-(4-fluorophényl)-4-oxobutyl]-3-[<sup>11</sup>C]méthyl-1-phényl-1,3,8-triazaspiro[4.5]décan-4-one  
*produit à usage radiodiagnostique*

mespiperona (<sup>11</sup>C)

8-[3-(*p*-fluorobenzoi)propil]-3-[<sup>11</sup>C]metil-1-fenil-1,3,8-triazaspiro[4.5]decan-4-ona  
*agente de radiodiagnóstico*

C<sub>23</sub>[<sup>11</sup>C]H<sub>28</sub>FN<sub>3</sub>O<sub>2</sub> 94153-50-1**mitiglinidum**


mitiglinide

(-)-(2*S*,3*a*,7*a*-*cis*)-α-benzylhexahydro-γ-oxo-2-isoindolinebutyric acid  
*antidiabétique*

mitiglinide

(-)-acide (2*S*)-2-benzyl-4-[(3*aR*,7*aS*)-octahydro-2*H*-isoindol-2-yl]-4-oxobutanoïque  
*antidiabétique*

mitiglinida

ácido (-)-(2*S*,3*a*,7*a*-*cis*)-α-bencilhexahidro-γ-oxo-2-isoindolinbutírico  
*antidiabético*C<sub>19</sub>H<sub>25</sub>NO<sub>3</sub> 145375-43-5**moxifloxacinum**


moxifloxacin

1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4*aS*,7*aS*)-octahydro-6*H*-pyrrolo[3,4-*b*]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid  
*antibactériale*

moxifloxacine

acide 1-cyclopropyl-6-fluoro-8-méthoxy-7-[(4*aS*,7*aS*)-octahydro-6*H*-pyrrolo[3,4-*b*]pyridin-6-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique  
*antibactérien*

moxifloxacina

ácido 1-ciclopropil-6-fluoro-1,4-dihidro-8-metoxi-7-[(4*aS*,7*aS*)-octahidro-6*H*-pirrolo[3,4-*b*]piridin-6-il]-4-oxo-3-quinolinacarboxílico  
*antibacteriano*C<sub>21</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>4</sub> 151096-09-2

**moxilubantum**

moxilubant

4-[[5-(*p*-amidinophenoxy)pentyl]oxy]-*N,N*-diisopropyl-3-methoxybenzamide  
*leukotriene receptor antagonist*


moxilubant

4-[[5-(4-carbamimidoylphénoxy)pentyl]oxy]-3-méthoxy-*N,N*-bis(1-méthyléthyl)benzamide  
*antagoniste du récepteur des leucotriènes*

moxilubant

4-[[5-(*p*-amidinofenoxi)pentil]oxi]-*N,N*-diisopropil-3-metoxibenzamida  
*antagonista del receptor de leucotrienos*C<sub>26</sub>H<sub>37</sub>N<sub>3</sub>O<sub>4</sub>

147398-01-4

**nelzarabinum**

nelzarabine

2-amino-β-D-arabinofuranosyl-6-methoxy-9*H*-purine  
*antineoplastique*


nélzarabine

9-(β-D-arabinofuranosyl)-6-méthoxy-9*H*-purin-2-amine  
*antineoplasique*

nelzarabina

2-amino-β-D-arabinofuranosil-6-metoxi-9*H*-purina  
*antineoplásico*C<sub>11</sub>H<sub>15</sub>N<sub>5</sub>O<sub>5</sub>

121032-29-9

**nepadutantum**

nepadutant

cyclo[*N*-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-*L*-asparaginy]-*L*-α-aspartyl-*L*-tryptophyl-*L*-phenylalanyl-*L*-2,3-diaminopropionyl-*L*-leucyl], cyclic (2-5)-peptide  
*tachykinin receptor antagonist*

népadutant


(2-5)-peptide cyclique du cyclo[[*N*<sup>4</sup>-(2-(acétylamino)-2-désoxy-β-D-glucopyranosyl)]-*L*-asparaginy]-*L*-aspartyl-*L*-tryptophyl-*L*-phénylalanyl-(3-amino-*L*-alanyl)-*L*-leucyl]  
*antagoniste de récepteurs de la tachykinine*

nepadutant

(2-5)-péptido cíclico de ciclo[N-(2-acetamido-2-desoxi-β-D-glucopiranosil)-L-asparaginil-L-α-aspartil-L-triptofil-L-fenilalanil-L-2,3-diaminopropionil-L-leucil]  
*antagonista del receptor de taquiquinina*

C<sub>45</sub>H<sub>58</sub>N<sub>10</sub>O<sub>13</sub>

183747-35-5



nepafenacum

nepafenac

2-(2-amino-3-benzoylphenyl)acetamide  
*non-steroid anti-inflammatory*

népafénac


2-(2-amino-3-benzoylphényl)acétamide  
*anti-inflammatoire non stéroïdien*

nepafenaco

2-(2-amino-3-benzoilfenil)acetamida  
*antiinflamatorio no esteroideo*

C<sub>15</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>

78281-72-8



nepicastatum

nepicastat

5-(aminomethyl)-1-[(S)-5,7-difluoro-1,2,3,4-tetrahydro-2-naphthyl]-4-imidazoline-2-thione  
*dopamine β-hydroxylase inhibitor*

népicastat


5-(aminométhyl)-1-[(2S)-5,7-difluoro-1,2,3,4-tétrahydronaphtalén-2-yl]-1,3-dihydro-2H-imidazole-2-thione  
*inhibiteur de la dopamine β-hydroxylase*

nepicastat

5-(aminometil)-1-[(S)-5,7-difluoro-1,2,3,4-tetrahydro-2-naftil]-4-imidazolina-2-tiona  
*inhibidor de la dopamina β-hidroxilasa*

C<sub>14</sub>H<sub>15</sub>F<sub>2</sub>N<sub>3</sub>S

173997-05-2

**nitisinonum**

nitisinone

2-( $\alpha,\alpha,\alpha$ -trifluoro-2-nitro-*p*-toluoyl)-1,3-cyclohexanedione  
4-hydroxyphenylpyruvate dioxigenase inhibitor

nitisinone


2-[2-nitro-4-(trifluorométhyl)benzoyl]cyclohexane-1,3-dione  
inhibiteur de la 4-hydroxyphénylpyruvate dioxygénase

nitisinona

2-( $\alpha,\alpha,\alpha$ -trifluoro-2-nitro-*p*-toluoil)-1,3-ciclohexanodiona  
inhibidor de la dioxigenasa del 4-hidroxifenilpiruvato

C<sub>14</sub>H<sub>10</sub>F<sub>3</sub>NO<sub>5</sub>

104206-65-7

**notatrexedum**

notatrexed

2-amino-6-methyl-5-(4-pyridylthio)-4(3*H*)-quinazolinone  
*antineoplastice*

notatrexed


2-amino-6-méthyl-5-[(pyridin-4-yl)sulfanyl]quinazolin-4(1*H*)-one  
*antineoplasique*

notatrexed

2-amino-6-metil-5-(4-piridiltio)-4(3*H*)-quinazolinona  
*antineoplásico*

C<sub>14</sub>H<sub>12</sub>N<sub>4</sub>OS

147149-76-6



**omapatrilatum**

omapatrilat

(4*S*,7*S*,10*aS*)-octahydro-4-[(*S*)- $\alpha$ -mercaptohydrocinnamamido]-5-oxo-7*H*-pyrido[2,1-*b*][1,3]thiazepine-7-carboxylic acid  
*angiotensin-converting enzyme inhibitor, endo peptidase inhibitor*

omapatrilate


acide (4*S*,7*S*,10*aS*)-5-oxo-4-[[2*S*]-3-phényl-2-sulfanylpropanoyl]amino]-octahydro-7*H*-pyrido[2,1-*b*][1,3]thiazépine-7-carboxylique  
*inhibiteur de l'enzyme de conversion de l'angiotensine, inhibiteur de l'endopeptidase*

omapatrilat

ácido (4*S*,7*S*,10*aS*)-octahidro-4-[(*S*)- $\alpha$ -mercaptohidrocinnamamido]-5-oxo-7*H*-pirido[2,1-*b*][1,3]tiazepina-7-carboxílico  
*inhibidor de la enzima conversora de la angiotensina, inhibidor de la endopeptidasa*

C<sub>19</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>S<sub>2</sub>

167305-00-2

**pamiteplasum**

pamiteplase

275-L-glutamic acid-(1-91)-(174-527)-plasminogen activator (human tissue-type protein moiety)  
*plasminogen activator*

pamitéplase

[275-acide L-glutamique]-(1-91)-(174-527)-activateur du plasminogène (de type tissulaire humain)  
*activateur du plasminogène*

pamiteplasa

275-ácido-L-glutámico -(1-91)-(174-527)-activador del plasminógeno (tipo tisular humano fracción proteica)  
*activador del plasminógeno*

C<sub>2172</sub>H<sub>3309</sub>N<sub>627</sub>O<sub>658</sub>S<sub>34</sub> 151912-42-4

SYQVICRDEK TQMIYQQHQS WLRPVLRSNR VEYWCNSGR  
 AQCHSVPVKS CSEPRCFNGG TCQQALYFSD FVCQCFEGFA  
 GKCCEIDTRA TSEGNSDCYF GNGSAYRGTH SLTESGASCL  
 PWNSMILIGK VYTAQNPSAQ ALGLGKHNYS RNPDGDAKPW  
 CHVLKNRRLT WEYCDVPSCS TCGLRQYSQP QFEIKGGLFA  
 DIASHPWQAA IFAKHRRSPG ERFLCGGILI SSCWILSAAH  
 CFQERFPPHH LTVILGRTYR VVPGEEEEQKF EVEKYIVHKE  
 FDDDTYNDI ALLQLKSDSS RCAQESSVVR TVCLPPADLQ  
 LPDWTECELS GYGKHEALSP FYSERLKEAH VRLYPSSRCT  
 SQHLLNRTVT DNMLCAGDTR SGGPQANLHD ACQGDSSGGL  
 VCLNDGRMTL VGIISWGLGC GQKDVPGVYT KVTNYLDWIR  
 DNMRP

\* glycosylation site

\* site de glycosylation

\* posición de glicosilación

**paricalcitolum**  
paricalcitol

(7*E*,22*E*)-19-nor-9,10-secoergosta-5,7,22-triene-1 $\alpha$ ,3 $\beta$ ,25-triol  
*vitamin D analogue*

## paricalcitol


(7*E*,22*E*)-(1*R*,3*R*)-19-nor-9,10-sécoergosta-5,7,22-triéne-1,3,25-triol  
*analogue de la vitamine D*

## paricalcitol

(7*E*,22*E*)-19-nor-9,10-secoergosta-5,7,22-trieno-1 $\alpha$ ,3 $\beta$ ,25-triol  
*análogo de la vitamina D*

C<sub>27</sub>H<sub>44</sub>O<sub>3</sub>

131918-61-1



**pemetrexedum**

pemetrexed

*N*-[*p*-[2-(2-amino-4,7-dihydro-4-oxo-1*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid  
*antineoplastico*

pémétréxed


acide (2*S*)-2-[[4-[2-(2-amino-4-oxo-4,7-dihydro-1*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)éthyl]benzoyl]amino]pentanedioïque  
*antineoplasique*

pemetrexed

ácido *N*-[*p*-[2-(2-amino-4,7-dihidro-4-oxo-1*H*-pirrolo[2,3-*d*]pirimidin-5-il)etil]benzoil]-L-glutámico  
*antineoplásico*

C<sub>20</sub>H<sub>21</sub>N<sub>5</sub>O<sub>6</sub>

137281-23-3

**perflenapentum**

perflenapent

dodecafluoropentane  
*ultrasound contrast agent*

perflénapent


dodécafluoropentane  
*produit de contraste pour des analyses ultrasoniques*

perflenapent

dodecafluoropentano  
*medio de contraste para análisis por ultrasonido*

C<sub>5</sub>F<sub>12</sub>

678-26-2

**perflisopentum**

perflisopent

nonafluoro-2-(trifluoromethyl)butane  
*ultrasound contrast agent*

perflisopent


nonafluoro-2-(trifluorométyl)butane  
*produit de contraste pour des analyses ultrasoniques*

perflisopent

nonafluoro-2-(trifluorometil)butano  
*medio de contraste para análisis por ultrasonido*

C<sub>5</sub>F<sub>12</sub>

594-91-2

**perifosinum**

perifosine

4-hydroxy-1,1-dimethylpiperidinium hydroxide, octadecyl hydrogen phosphate, inner salt  
*antineoplastique*

pérfosine


1,1-diméthyl-4-[[[octadécyloxy]oxydophosphoryl]oxy]pipéridinium  
*antinéoplasique*

perifosina

1,1-dimetil-4-[[[octadeciloxi]oxidofosforil]oxi]piperidinio  
*antineoplásico*

C<sub>25</sub>H<sub>52</sub>NO<sub>4</sub>P

157716-52-4

**pexigananum**

pexiganan

glycyl-L-isoleucylglycyl-L-lysyl-L-phenylalanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-lysyl-L-lysyl-L-phenylalanylglycyl-L-lysyl-L-alanyl-L-phenylalanyl-L-valyl-L-lysyl-L-isoleucyl-L-leucyl-L-lysyl-L-lysineamide  
*antibacterial*

pexiganan

glycyl-L-isoleucyl-glycyl-L-lysyl-L-phénylalanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-lysyl-L-lysyl-L-phénylalanyl-glycyl-L-lysyl-L-alanyl-L-phénylalanyl-L-valyl-L-lysyl-L-isoleucyl-L-leucyl-L-lysyl-L-lysineamide  
*antibactérien*

pexiganán

glicil-L-isoleucilglicil-L-lisil-L-fenilalanil-L-leucil-L-lisil-L-lisil-L-alanil-L-lisil-L-lisil-L-fenilalanilglicil-L-lisil-L-alanil-L-fenilalanil-L-valil-L-lisil-L-isoleucil-L-leucil-L-lisil-L-lisinaamida  
*antibacteriano*


C<sub>122</sub>H<sub>210</sub>N<sub>32</sub>O<sub>22</sub>

172820-23-4


Gly-Ile-Gly-Lys-Phe-Leu-Lys-Lys-Ala-Lys-Lys-Phe-

Gly-Lys-Ala-Phe-Val-Lys-Ile-Leu-Lys-Lys-NH<sub>2</sub>

<b>pibutidinum</b>	
pibutidine	3-amino-4-[[[(Z)-4-[4-(piperidinomethyl)-2-pyridyl]oxy]-2-butenyl]amino]-3-cyclobutene-1,2-dione <i>histamine H<sub>2</sub>-receptor antagonist</i>
pibutidine	3-amino-4-[[[(2Z)-4-[4-(pipéridin-1-ylméthyl)pyridin-2-yl]oxy]but-2-ényl]amino]cyclobut-3-ène-1,2-dione <i>antagoniste des récepteurs H<sub>2</sub> de l'histamine</i>
pibutidina	3-amino-4-[[[(Z)-4-[4-(piperidinometil)-2-piridil]oxi]-2-butenil]amino]-3-ciclobuteno-1,2-diona <i>antagonista de los receptores H<sub>2</sub> de la histamina</i>
	C <sub>19</sub> H <sub>24</sub> N <sub>4</sub> O <sub>3</sub> 103922-33-4




<b>pregabalinum</b>	
pregabalin	(S)-3-(aminomethyl)-5-methylhexanoic acid <i>anticonvulsant</i>
prégabaline	acide (3S)-3-(aminométhyl)-5-méthylhexanoïque <i>anticonvulsivant</i>
pregabalina	ácido (S)-3-(aminometil)-5-metilhexanoico <i>anticonvulsivo</i>
	C <sub>8</sub> H <sub>17</sub> NO <sub>2</sub> 148553-50-8



<b>prucalopridum</b>	
prucalopride	4-amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidyl]-7-benzofurancarboxamide <i>prokinetic agent</i>
prucalopride	4-amino-5-chloro-N-[1-(3-méthoxypropyl)pipéridin-4-yl]-2,3-dihydrobenzofurane-7-carboxamide <i>accélérateur du transit intestinal</i>
prucaloprida	4-amino-5-cloro-2,3-dihidro-N-[1-(3-metoxipropil)-4-piperidil]-7-benzofurancarboxamida <i>estimulante de la motilidad intestinal</i>

C<sub>18</sub>H<sub>26</sub>ClN<sub>3</sub>O<sub>3</sub>

179474-81-8



**rapacuronii bromidum**  
rapacuronium bromide

1-allyl-1-(3 $\alpha$ ,17 $\beta$ -dihydroxy-2 $\beta$ -piperidino-5 $\alpha$ -androstan-16 $\beta$ -yl)piperidinium bromide, 3-acetate 17-propionate  
*neuromuscular receptor antagonist*

bromure de rapacuronium


bromure de 1-[3 $\alpha$ -(acétyloxy)-2 $\beta$ -(pipéridin-1-yl)-17 $\beta$ -(propanoyloxy)-5 $\alpha$ -androstan-16 $\beta$ -yl]-1-(prop-2-ényl)pipéridinium  
*antagoniste des récepteurs neuro-musculaires*

bromuro de rapacuronio

bromuro de 1-allyl-1-(3 $\alpha$ ,17 $\beta$ -dihidroxi-2 $\beta$ -piperidino-5 $\alpha$ -androstan-16 $\beta$ -il)piperidinio, 3-acetato 17-propionato  
*antagonista de los receptores neuromusculares*

C<sub>37</sub>H<sub>61</sub>BrN<sub>2</sub>O<sub>4</sub>

156137-99-4



**rifalazilum**  
rifalazil

(2*S*,16*Z*,18*E*,20*S*,21*S*,22*R*,23*R*,24*R*,25*S*,26*R*,27*S*,28*E*)-5,12,21,23,25-pentahydroxy-10-(4-isobutyl-1-piperazinyl)-27-methoxy-2,4,16,20,22,24,26-heptamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)-6*H*-benzofuro[4,5-*a*]phenoxazine-1,6,15(2*H*)-trione 25-acetate  
*antibacterial*

rifalazil


acétate de (16*Z*,18*E*,28*E*)-(2*S*,20*S*,21*S*,22*R*,23*R*,24*R*,25*S*,26*R*,27*S*)-5,12,21,23-tétrahydroxy-27-méthoxy-2,4,16,20,22,24,26-heptaméthyl-10-[4-(2-méthylpropyl)pipérazin-1-yl]-1,6,15-trioxo-1,2-dihydro-2,7-(époxy-pentadéca[1,11,13]triènimino)-6*H*-benzofuro[4,5-*a*]phénoxazin-25-yle  
*antibactérien*

rifalazilo

25-acetato de (2*S*,16*Z*,18*E*,20*S*,21*S*,22*R*,23*R*,24*R*,25*S*,26*R*,27*S*,28*E*)-5,12,21,23,25-pentahidroxi-10-(4-isobutil-1-piperazinil)-27-metoxi-2,4,16,20,22,24,26-heptametil-2,7-(epoxipentadeca[1,11,13]trienimino)-6*H*-benzofuro[4,5-*a*]fenoxazina-1,6,15(2*H*)-triona  
*antibacteriano*

C<sub>51</sub>H<sub>64</sub>N<sub>4</sub>O<sub>13</sub>

129791-92-0

**robalzotanum**

robalzotan

(*R*)-3-(dicyclobutylamino)-8-fluoro-5-chromancarboxamide  
*serotonin receptor agonist*

robalzotan


(3*R*)-3-(dicyclobutylamino)-8-fluoro-3,4-dihydro-2*H*-chromène-5-carboxamide  
*agoniste des récepteurs de la sérotonine*

robalzotán

(*R*)-3-(dicyclobutylamino)-8-fluoro-5-cromancarboxamida  
*agonista de los receptores de la serotonina*

C<sub>18</sub>H<sub>23</sub>FN<sub>2</sub>O<sub>2</sub>

169758-66-1

**rosiglitazonum**

rosiglitazone

(±)-5-[*p*-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione  
*antidiabetic*

rosiglitazone


(5*RS*)-5-[4-[2-[méthyl(pyridin-2-yl)amino]éthoxy]benzyl]thiazolidine-2,4-dione  
*antidiabétique*

rosiglitazona

(±)-5-[*p*-[2-(metil-2-piridilamino)etoxi]bencil]-2,4-tiazolidinadiona  
*antidiabético*

C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>S

122320-73-4

**seocalcitolum**

seocalcitol

(5Z,7E,22E,24E)-24a,26a,27a-trihomo-9,10-secocholesta-5,7,10(19),22,24-pentaene-1 $\alpha$ ,3 $\beta$ ,25-triol  
*vitamin D analogue*

séocalcitol


(5Z,7E,22E,24E)-(1S,3F)-24a,26a,27a-trihomo-9,10-sécocholesta-5,7,10(19),22,24-pentaène-1,3,25-triol  
*analogue de la vitamine D*

seocalcitol

(5Z,7E,22E,24E)-24a,26a,27a-trihomo-9,10-secocolesta-5,7,10(19),22,24-pentaeno-1 $\alpha$ ,3 $\beta$ ,25-triol  
*análogo de la vitamina D*

C<sub>30</sub>H<sub>46</sub>O<sub>3</sub>

134404-52-7

**silperisonum**

silperisone

1-[[(*p*-fluorobenzyl)dimethylsilyl]methyl]piperidine  
*central muscle relaxant*

silpérisonne


1-[[((4-fluorobenzyl)diméthylsilyl)méthyl]pipéridine  
*myorelaxant central*

silperisona

1-[[(*p*-fluorobencil)dimetilsilil]metil]piperidina  
*miorelajante central*

C<sub>15</sub>H<sub>24</sub>FNSi


140944-31-6





C<sub>17</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>

148408-65-5

**targininum**

targinine

*N*<sup>5</sup>-(méthylamidino)-L-ornithine  
nitric oxide synthase inhibitor

targinine


acide (2*S*)-2-amino-5-(3-méthylguanidino)pentanoïque  
inhibiteur de l'oxyde nitrique synthase

targinina

*N*<sup>5</sup>-(metilamidino)-L-ornitina  
inhibidor de la sintetasa del óxido nítrico

C<sub>7</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>

17035-90-4

**technetii (<sup>99m</sup>Tc) apcitudum**technetium (<sup>99m</sup>Tc) apcitude

sodium hydrogen [*N*-(mercaptoacetyl)-*D*-tyrosyl-*S*-(3-aminopropyl)-*L*-cysteinylglycyl-*L*- $\alpha$ -aspartyl-*L*-cysteinylglycylglycyl-*S*-(acetamidomethyl)-*L*-cysteinylglycyl-*S*-(acetamidomethyl)-*L*-cysteinylglycylglycyl-*L*-cysteinamide cyclic (1-5)-sulfidato(5-)-*N*<sup>11</sup>,*N*<sup>12</sup>,*N*<sup>13</sup>,*S*<sup>13</sup>]oxo[<sup>99m</sup>Tc]technetate(V)  
radiodiagnostic agent

technétium (<sup>99m</sup>Tc) apcitude


hydrogéno [(1-5)-(sulfure cyclique) du [*N*-(sulfanylacétyl)-*D*-tyrosyl]-[*S*-(3-aminopropyl)-*L*-cystéinyl]-glycyl-*L*-aspartyl-*L*-cystéinyl-glycyl-glycyl-[*S*-[(acétylamino)méthyl]-*L*-cystéinyl]-glycyl-[*S*-[(acétylamino)méthyl]-*L*-cystéinyl]-glycyl-glycyl-*L*-cystéinamidato(5-)-*N*<sup>11</sup>,*N*<sup>12</sup>,*N*<sup>13</sup>,*S*<sup>13</sup>]oxo[<sup>99m</sup>Tc]technetate(V) de sodium  
produit à usage radiodiagnostique

tecnecio (<sup>99m</sup>Tc) apcítida

hidrógeno [*N*-(mercaptoacetil)-*D*-tiroxil-*S*-(3-aminopropil)-*L*-cisteinilglicil-*L*- $\alpha$ -aspartil-*L*-cisteinilglicilglicil-*S*-(acetamidometil)-*L*-cisteinilglicil-*S*-(acetamidometil)-*L*-cisteinilglicilglicil-*L*-cisteinamida (1-5)-sulfidato cíclico (5-)-*N*<sup>11</sup>,*N*<sup>12</sup>,*N*<sup>13</sup>,*S*<sup>13</sup>]oxo[<sup>99m</sup>Tc]tecnetato(V) de sodio  
agente de radiodiagnóstico

C<sub>51</sub>H<sub>73</sub>N<sub>17</sub>NaO<sub>20</sub>S<sub>5</sub><sup>99m</sup>Tc

178959-14-3

**temocaprilatum**

temocaprilat

(+)-(2*S*,6*R*)-6-[[[(1*S*)-1-carboxy-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5*H*)-acetic acid  
angiotensin-converting enzyme inhibitor

témocaprilate


(+)-acide 2-[[[(2*S*,6*R*)-6-[[[(1*S*)-1-carboxy-3-phénylpropyl]amino]-5-oxo-2-(thiophén-2-yl)tétrahydro-1,4-thiazépin-4(5*H*)-yl]acétique  
inhibiteur de l'enzyme de conversion de l'angiotensine

temocaprilato

ácido (+)-(2*S*,6*R*)-6-[[[(1*S*)-1-carboxi-3-fenilpropil]amino]tetrahidro-5-oxo-2-(2-tienil)-1,4-tiazepina-4(5*H*)-acético  
inhibidor de la enzima conversora de la angiotensina

C<sub>21</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub>

110221-53-9

**thyrotropinum alfa**

thyrotropin alfa

thyrotropin (human  $\beta$ -subunit protein moiety), complex with chorionic gonadotropin (human  $\alpha$ -subunit protein moiety)  
thyrotropin releasing hormone (TRH) analog

thyrotropine alfa

thyrotropine (humaine, partie protéique de 118 aminoacides de la sous-unité  $\beta$ ) complexée à la gonadotropine chorionique (humaine, partie protéique de 92 aminoacides de la sous-unité  $\alpha$ )  
analoge de l'hormone de libération de la thyrotropine

tirotopina alfa

tirotopina (humana, fracción proteica de 118 aminoácidos de la subunidad  $\beta$ ), complejo con gonadotropina coriónica (humana, fracción proteica de 92 aminoácidos de la subunidad  $\alpha$ )  
análogo de la hormona liberadora de tirotopina

C<sub>1039</sub>H<sub>1602</sub>N<sub>274</sub>O<sub>307</sub>S<sub>27</sub>

APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSTRAYPTP  
 LRSKKTMLVQ KNVTSSESTCC VAKSYNRVTV MGGFKVENHT  
 ACHCSTCYHH KS

FCIPTEYTMH IERRECAVCL TINTTICAGY CMTRDINGKL  
 FLPKYALSQD VCTYRDFIYR TVEIPGCPLH VAPYFSYPVA  
 LSCKCGKCNT DYSDCIHEAI KTNVCTKPQK SYLVGFSV

**tifacoginum**

tifacogin

*N*-L-alanylblood-coagulation factor LACI (human clone λ P9 protein moiety reduced)  
*anticoagulant*

tifacogine

*N*-L-alanylfacteur de coagulation sanguine LACI (partie protéique réduite produite par le clone humain λ P9)  
*anticoagulant*

tifacogina

*N*-L-alanilfactor de coagulación sanguínea LACI (fracción protéica reducida producida por el clón humano λ P9)  
*anticoagulante*

C<sub>1400</sub>H<sub>2167</sub>N<sub>395</sub>O<sub>422</sub>S<sub>23</sub> 148883-56-1

ADSEEDDEHT IITDTELPPL KLMHSFCAFK ADDGPCKAIM  
 KRFFFNIFTR QCEEFIYGGC EGNQNRFESL EECKKMCTRD  
 NANRIKTTTL QQEKPDFCFL EEDPGICRGY ITRYFYNNQT  
 KQCERFKYGG CLGNMNNFET LEECKNICED GPNGFQVDNY  
 GTQLNAVNS LTPQSTKVPS LFEFHGPSWC LTPADRGLCR  
 ANENRFYNS VIGKCRPFKY SGCNGNENNF TSKQECLRAC  
 KKGFIQRISK GGLIKTKRKR KKQRVKIAYE EIFVKNM

**tobicillinum**

tobicillin

(+)-α-hydroxy-*m*-tolyl (2*S*,5*R*,6*R*)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate, isobutyrate (ester)  
*antibiotic (vet.)*

tobicilline


(2*S*,5*R*,6*R*)-3,3-diméthyl-7-oxo-6-[(2-phénylacétyl)amino]-4-thia-1-azabicyclo-[3.2.0]heptane-2-carboxylate de 3-[[[(2-méthylpropanoyl)oxy]méthyl]phényle  
*antibiotique (vét.)*

tobicillina

(2*S*,5*R*,6*R*)-3,3-dimetil-7-oxo-6-(2-fenilacetamido)-4-tia-1-azabicio-[3.2.0]heptano-2-carboxilato de (+)-α-hidroxi-*m*-tolilo, isobutirato (éster)  
*antibiótico (vet.)*

C<sub>27</sub>H<sub>30</sub>N<sub>2</sub>O<sub>6</sub>S

151287-22-8

**trastuzumabum**

trastuzumab

immunoglobulin G 1 (human-mouse monoclonal rhuMab HER2  $\gamma_1$ -chain anti-human p185<sup>c-erbB2</sup> receptor), disulfide with human-mouse monoclonal rhuMab HER2 light chain, dimer  
*immunomodulator*

trastuzumab

immunoglobuline G 1 (chaîne  $\gamma_1$  de l'anticorps monoclonal de souris humanisé rhuMab HER2 dirigé contre le récepteur humain p185<sup>c-erbB2</sup>), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris humanisé rhuMab HER2  
*immunomodulateur*

trastuzumab

inmunoglobulina G 1 (cadena  $\gamma_1$  del anticuerpo monoclonal humanizado de ratón rhuMab HER2 dirigido contra el receptor humano p185<sup>c-erbB2</sup>), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón rhuMab HER2  
*inmunomodulador*

180288-69-1

**tremacamrum**

tremacamra

1-453-glycoprotein ICAM I (human reduced)  
*antiviral*

tremacamra

glycoprotéine comprenant 453 amino-acides, constituée du domaine extracellulaire de la molécule d'adhésion intracellulaire-1 humaine (ICAM-1), obtenue par génie génétique  
*antiviral*

tremacamra

1-453-glicoproteína ICAM I (humana reducida)  
*antiviral*

155576-45-7

QTSVSPSKVI LPRGGSVLVT CSTSCDQPKL LGIETPLPKK  
 ELLLPGNRKR VYELSNVQED SQPMCYSNCP DGQSTAKTFL  
 TVYWTPERVE LAPLPSWQPV GKNLTLCRQV EGGAPRANLT  
 VVLLRGEKEL KREPAVGEP A EVTTTTLVRR DHHGAFNSCR  
 TELDLRPQGL ELFENTSAPY QLQTFVLPAT PPQLVSPRVL  
 EVDTQGTVVC SLDGLFPVSE AQVHLALGDQ RLNPTVTYGN  
 DSFSAKASVS VTAEDEGTQR LTCAVILGNQ SQETLQVTI  
 YSFPAPNVIL TKPEVSEGTE VTVKCEAHR AKVTLNGVPA  
 QPLGPRAQLL LKATPEDNGR SFSCSATLEV AGQLIHKNT  
 RELRVLYGPR LDERDCPGNW TWPENSQQTP MCQAWGNPLP  
 ELKCLKDGT F PLPIGESVTV TRDLEGTLYC RARSTQGEVT  
 REVTVNVLSP RYE

**valganciclovirum**

valganciclovir

L-valine, ester with 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine  
*antiviral*

valganciclovir


(2*S*)-2-amino-3-méthylbutanoate de (2*RS*)-2-[(2-amino-6-oxo-1,6-dihydro-9*H*-  
 purin-9-yl)méthoxy]-3-hydroxypropyle  
*antiviral*

valganciclovir

L-valinato de 9-[[2-hidroxi-1-(hidroximetil)etoxi]metil]guanina  
*antiviral*

C<sub>14</sub>H<sub>22</sub>N<sub>6</sub>O<sub>5</sub>

175865-60-8

**xaliprodenum**

xaliproden

1,2,3,6-tetrahydro-1-[2-(2-naphthyl)ethyl]-4-( $\alpha,\alpha,\alpha$ -trifluoro-*m*-tolyl)pyridine  
*nootropic agent*


xaliprodenè

1-[2-(naphthalén-2-yl)éthyl]-4-[3-(trifluorométhyl)phényl]-1,2,3,6-  
 tétrahydropyridine  
*nootrope*

xaliprodeno

1,2,3,6-tetrahydro-1-[2-(2-naftil)etil]-4-( $\alpha,\alpha,\alpha$ -trifluoro-*m*-tolil)piridina  
*nootropo*C<sub>24</sub>H<sub>22</sub>F<sub>3</sub>N

135354-02-8

**ziconotidum**

ziconotide

L-cysteinyl-L-lysylglycyl-L-lysylglycyl-L-alanyl-L-lysyl-L-cysteinyl-L-seryl-L-  
arginyl-L-leucyl-L-methionyl-L-tyrosyl-L- $\alpha$ -aspartyl-L-cysteinyl-L-cysteinyl-L-  
threonylglycyl-L-seryl-L-cysteinyl-L-arginyl-L-serylglycyl-L-lysyl-L-cysteinamide  
cyclic (1-16), (8-20), (15-25)-tris(disulfide)  
*analgesic, neural anti-ischemic*


ziconotide

(1-16),(8-20),(15-25)-tris(disulfure cyclique) du L-cystéinyl-L-lysyl-glycyl-L-  
lysyl-glycyl-L-alanyl-L-lysyl-L-cystéinyl-L-séryl-L-arginyl-L-leucyl-L-méthionyl-L-  
tyrosyl-L-aspartyl-L-cystéinyl-L-cystéinyl-L-thréonyl-glycyl-L-séryl-L-cystéinyl-L-  
arginyl-L-séryl-glycyl-L-lysyl-L-cystéinamide  
*analgésique, anti-ischémique neural*

ziconotida

(1-16), (8-20), (15-25)-tris(disulfuro cíclico) de L-cisteinil-L-lisilglicil-L-lisilglicil-  
L-alanil-L-lisil-L-cisteinil-L-seril-L-arginil-L-leucil-L-metionil-L-tirosil-L- $\alpha$ -aspartil-L-  
cisteinil-L-cisteinil-L-treonilglicil-L-seril-L-cisteinil-L-arginil-L-serilglicil-L-lisil-L-  
cisteinamida  
*analgésico, anti-ischémico neural*C<sub>102</sub>H<sub>172</sub>N<sub>36</sub>O<sub>32</sub>S<sub>7</sub>

107452-89-1



---

**AMENDMENTS TO PREVIOUS LISTS  
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES  
MODIFICACIONES A LAS LISTAS ANTERIORES**

**Proposed International Nonproprietary Names (Prop. INN): List 64**  
*(WHO Drug Information, Vol. 4, No. 4, 1990)*

p. 20 **reviparinum natricum**  
reviparin sodium

*replace the definition by the following:*

Sodium salt of a low molecular mass heparin that is obtained by nitrous acid depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 2-*O*-sulfo- $\alpha$ -L-idopyranosuronic acid structure at the non-reducing end and a 6-*O*-sulfo-2,5-anhydro-D-mannitol structure at the reducing end of their chain; the mass-average molecular mass ranges between 3150 and 5150, with a characteristic value of about 4150; the degree of sulfatation is about 2.1 per disaccharidic unit.

**Dénominations communes internationales proposées (DCI Prop.): Liste 64**  
*(Informations pharmaceutiques OMS, Vol. 4, No. 4, 1990)*

p. 20 **reviparinum natricum**  
réviparine sodique

*remplacer la description suivante:*

Sel sodique d'une héparine de basse masse moléculaire obtenue par dépolymérisation, au moyen d'acide nitreux, d'héparine de muqueuse intestinale de porc; la majorité des composants de la réviparine sodique possèdent une structure acide 2-*O*-sulfo- $\alpha$ -L-idopyranosuronique à l'extrémité non réductrice de leur chaîne et une structure 6-*O*-sulfo-2,5-anhydro-D-mannitol à l'extrémité réductrice de leur chaîne; la masse moléculaire relative moyenne est de 3150 à 5150, avec une valeur caractéristique de 4150 environ; le degré de sulfatation est 2.1 environ par unité disaccharidique.

**Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Liste 64**  
*(Información Farmacéutica, OMS, Vol. 4, No. 4, 1990)*


p. 20 **reviparinum natricum**  
reviparina sódica

*sustituyase la descripción por la siguiente:*

Sal sódica de una heparina de baja masa molecular obtenida por despolimerización con ácido nítrico de la heparina de la mucosa intestinal del cerdo; la mayoría de los compuestos tienen una estructura de ácido 2-*O*-sulfo- $\alpha$ -L-idopiranosurónico en el extremo no reductor y una estructura de 6-*O*-sulfo-2,5-anhidro-D-manitol en el extremo reductor de la cadena; la masa molecular relativa media está entre 3150 y 5150; un valor característico de 4150 aproximadamente; el grado de sulfatación es de 2.1 por unidad de disacárido.

**Proposed International Nonproprietary Names (Prop. INN): List 71****Dénominations communes internationales proposées (DCI Prop.): Liste 71****Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Liste 71***(WHO Drug Information, Vol. 8, No. 2, 1994)*

p. 8	<i>delete/supprimer/suprimase</i>	<i>insert/insérer/insértese</i>
	dacliximabum	daclizumabum
	dacliximab	daclizumab
	dacliximab	daclizumab
	dacliximab	daclizumab
p. 20	<b>teverelixum</b>	<i>replace the chemical name and the graphic formula by the following:</i>
	teverelix	<i>N</i> -acetyl-3-(2-naphthyl)-D-alanyl- <i>p</i> -chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl- <i>N</i> <sup>6</sup> -carbamoyl-D-lysyl-L-leucyl- <i>N</i> <sup>6</sup> -isopropyl-L-lysyl-L-prolyl-D-alaninamide
	tévérélix	<i>remplacer le nom chimique et la formule développée par:</i>
		[ <i>N</i> -acétyl-3-(naphtalén-2-yl)-D-alanyl]-[4-chloro-D-phénylalanyl]-[3-(pyridin-3-yl)-D-alanyl]-L-séryl-L-tyrosyl-[ <i>N</i> <sup>6</sup> -(carbamoyl)-D-lysyl]-L-leucyl-[ <i>N</i> <sup>6</sup> -(1-méthyléthyl)-L-lysyl]-L-prolyl-D-alaninamide
	teverelix	<i>sustituyase el nombre químico y la fórmula desarrollada por:</i>
		[ <i>N</i> -acetil-3-(naftalen-2-il)-D-alanil]-[4-cloro-D-fenilalanil]-[3-(piridin-3-il)-D-alanil]-L-seril-L-tirosil-[ <i>N</i> <sup>6</sup> -(carbamoil)-D-lisil]-L-leucil-[ <i>N</i> <sup>6</sup> -(1-metiletil)-L-lisil]-L-prolil-D-alaninamida

**Proposed International Nonproprietary Names (Prop. INN): List 75****Dénominations communes internationales proposées (DCI Prop.): Liste 75****Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Liste 75***(WHO Drug Information, Vol. 10, No. 2, 1996)*

p. 91	<i>delete/supprimer/suprimase</i>	<i>insert/insérer/insértese</i>
	anseculinum	ensaculinum
	anseculin	ensaculin
	anséculine	ensaculine
	anseculina	ensaculina

**Proposed International Nonproprietary Names (Prop. INN): List 76**  
**Dénominations communes internationales proposées (DCI Prop.): Liste 76**  
**Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Liste 76**  
*(WHO Drug Information, Vol. 10, No. 4, 1996)*

- p. 196 *delete/supprimer/suprimase* *insert/insérer/insértese*  
 balaperidonum balaperidonum  
 balaperidone balaperidone  
 balapéridone béalapéridone  
 balaperidona balaperidona
- p. 197 **bimocloclolum**  
 bimocloclomol  
*replace the chemical name by the following:*  
 (±)-N-(2-hydroxy-3-piperidinopropoxy)nicotinimidoyl chloride
- p. 213 **opratonii iodidum**  
 opratonium iodide  
*replace the chemical name by the following:*  
 trimethyl[3-(10-undecenamido)propyl]ammonium iodide  
 ioduro de opratonio  
*sustituyase el nombre químico por lo siguiente:*  
 ioduro de trimetil[3-(10-undecenamido)propil]amonio
- p. 216 **sabcomelinum**  
 sabcomeline  
*replace the action and use statement by the following:*  
 muscarinic receptor agonist  
 sabcoméline  
*remplacer le terme d'action pharmacologique par le suivant:*  
 agoniste de récepteurs muscariniques  
 sabcomelina  
*sustituyase el término de acción farmacológica por el siguiente:*  
 agonista de los receptores muscarínicos
- p. 217 **tasonerminum**  
 tasonermin  
 tasonermine  
 tasonermina  
*replace the graphic formula by the following:*  
*remplacer la formule développée par la suivante:*  
*sustituyase la fórmula desarrollada por la siguiente:*

```

VRSSSRTPSD  KVAHVVANP  QAEGQLQWLN  RRANALLANG
VELRDNQLVV  PSEGLYLIYS  QVLFKGQGCP  STHVLLTHTI
SRIAVSYQTK  VNLLSAIKSP  CQRETPEGAE  AKPWYEPIYL
GGVFQLEKGD  RLSAEINRPD  YLDFAESGQV  YFGIIAL

```

**Proposed International Nonproprietary Names (Prop. INN): List 77****Dénominations communes internationales proposées (DCI Prop.): Liste 77****Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Liste 77***(WHO Drug Information, Vol. 11, No. 2, 1997)*

- p. 90 **eplerenonum**  
éplérénone  
*remplacer l'indication par la suivante:*  
antagoniste de récepteurs de l'aldostérone  
eplerenona  
*sustituyase la acción y uso por la siguiente:*  
antagonista de los receptores de aldosterona
- p. 96 **opanaxilum**  
opanaxil  
*remplacer l'indication par la suivante:*  
antihyperlipidémiant
- p. 104 **nadroparinum calcium**  
nadroparin calcium  
*replace the definition by the following:*  
Calcium salt of a low molecular mass heparin obtained by nitrous acid depolymerization of heparin from pork intestinal mucosa, followed by fractionation to eliminate selectively most of the chains with a molecular mass lower than 2000; the majority of the components have a 2-*O*-sulfo- $\alpha$ -L-idopyranosuronic acid structure at the non-reducing end and a 6-*O*-sulfo-2,5-anhydro-D-mannitol structure at the reducing end of their chain; the mass-average molecular mass ranges between 3600 and 5000 with a characteristic value of about 4300; the degree of sulfatation is about 2.1 per disaccharidic unit.
- p. 109 nadroparine calcique  
*remplacer la description par la suivante:*  
Sel calcique d'une héparine de basse masse moléculaire obtenue par dépolymérisation, au moyen d'acide nitreux, d'héparine de muqueuse intestinale de porc; la majorité des composants de la nadroparine sodique possèdent une structure acide 2-*O*-sulfo- $\alpha$ -L-idopyranosuronique à l'extrémité non réductrice de leur chaîne et une structure 6-*O*-sulfo-2,5-anhydro-D-mannitol à l'extrémité réductrice de leur chaîne; la masse moléculaire relative moyenne est de 3600 à 5000, avec une valeur caractéristique de 4300 environ; le degré de sulfatation est 2.1 environ par unité disaccharidique.
- p. 110 nadroparina cálcica  
*sustituyase la descripción por la siguiente:*  
Sal cálcica de una heparina de baja masa molecular obtenida por despolimerización con ácido nitroso de la heparina de la mucosa intestinal de cerdo seguida de fraccionamiento a fin de eliminar selectivamente la mayor parte de las cadenas de masa molecular inferior a 2000; la mayoría de los componentes tienen una estructura de ácido 2-*O*-sulfo- $\alpha$ -L-idopiranosurónico en el extremo no reductor y una estructura de 6-*O*-sulfo-2,5-anhidro-D-manitol en el extremo reductor de la cadena; la masa molecular relativa media es de 3600 a 5000, con un valor característico de 4300 aproximadamente; el grado de sulfatación es de 2.1 por unidad de disacárido.

**Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* ont été publiés avec la liste 77 des DCI proposées et seront, à nouveau, publiés avec la prochaine liste.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.



## **The Use of Common Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances**

This document lists common stems for international nonproprietary names (INN) for pharmaceutical substances for which chemical or pharmacological categories have been established. These stems and their definitions are intended to guide the selection of new INNs (common drug names) for substances that belong to an established series of related compounds. The list aims to encourage consistency in the designation of common names while also protecting the principle that INNs are public property. Produced as a working document, the list is of interest to manufacturers engaged in research and development, trademark officers, and national regulatory authorities, teachers of medicinal chemistry and pharmacology.

The document has two main parts. The first, presented in tabular form, gives common stems and their definitions for 23 categories of drugs, moving from CNS depressants and stimulants, through cardiovascular agents and anti-infectives, to vitamins and hormone preparations.

The second and most extensive part provides an alphabetical list of recommended stems and the corresponding family of INNs. Information on each stem includes a succinct definition, chemical formula where appropriate, and the relevant series of related INNs. Each entry also includes a reference to the list where the proposed name was published, and where more comprehensive information can be obtained.

Annexed to the document is an explanation of the stem system adopted for use when selecting international nonproprietary names for monoclonal antibodies.

### **The Use of Common Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances**

1997, vi + 130 pages (English)  
WHO/PHARM/ S/NOM 15 Rev.34  
Sw.fr. 18.-/US \$16.20  
In developing countries: Sw.fr. 12.60  
Order no. 1933083